Also known as: BCMA-directed CAR T-cell therapy, BCMA-directed CAR T therapy, BCMA-directed CAR-T therapy
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
CAR T-cell therapy is delivering high remission rates for multiple myeloma patients, with improved handoff communication reducing infection risks. FDA-approved BCMA-targeting products show response rates from 72% to 98% in heavily pretreated patients.
Preclinical and early clinical data show carfilzomib can restore BCMA expression on myeloma cells after CAR T-cell therapy failure, with 6 of 10 patients experiencing renewed clinical responses in a small study.
Gilead Sciences entered a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 contingent value right, representing an implied equity value of $7.8 billion. The acquisition provides Gilead with full control of anito-cel, an investigational BCMA-directed CAR T-cell therapy for multiple myeloma.
